SimpleFunctions
Winner-take-all answer·4 source contracts·Kalshi 4·refreshed just now·Closes Aug 1, 2026 · 36d

What will the FDA's decision be on Gedatolisib by Celcuity Inc. in July 2026

Leader sits at 76% across 4 bound outcomes, runner-up at 9%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.

Leader probability

76%

Full Approval

runner-up 9¢leader 76¢

Outcomes

4

winner-take-all

Runner-up

Denied (CRL Issued)

Spread

67pp

dominant leader

24h volume

$23

thin orderbook

Closes

Aug 1, 2026

36 days

Venue

Kalshi

4 bound

30-day trend

0%50%100%-30d-3w-2w-1wtodayFull Approval: 75% (12 days, 7 points)Full Approval: 75% on 2026-06-25Denied (CRL Issued): 7% (12 days, 6 points)Denied (CRL Issued): 7% on 2026-06-20Conditional / Accelerated Approval: 5% (12 days, 11 points)Conditional / Accelerated Approval: 5% on 2026-06-25
Full Approval75¢Denied (CRL Issued)7¢Conditional / Accelerated Approval5¢
Top 3 candidates by current price · 12d

Bracket family

How the bracket ladder is priced.

Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.

Analysis

Markets are pricing an approximately 75% likelihood that the FDA will grant full approval for Gedatolisib (a Celcuity Inc. oncology candidate) by the end of July 2026. This probability reflects the drug's regulatory progress toward a potential approval decision within the specified timeframe. The current level is driven by the timing of the FDA review cycle and the therapeutic area's historical approval rates for similar agents. The primary catalyst would be the formal FDA decision, which typically follows completion of the agency's standard or priority review period. Approval odds would increase if recent clinical data demonstrate efficacy and safety improvements over existing treatments, while they would decline if the FDA issues a complete response letter requesting additional data, or if the decision timeline extends beyond July.

  • FDA review timeline completion: whether the agency's decision date falls within July 2026 versus extending into later months
  • Recent clinical trial outcomes for Gedatolisib: efficacy and safety profile relative to competitor drugs in the same indication
  • Celcuity's regulatory communication history: any preliminary feedback or deficiency letters from the FDA before July
  • Historical approval rates for oncology candidates in this drug class and indication
  • Competitive landscape: whether other similar agents recently gained approval, which could influence FDA precedent and decision momentum

What moved the line

  • Jun 20Full Approval3pp7673¢ · Kalshi
  • Jun 21No Decision3pp63¢ · Kalshi

Recently closed in general

These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.

More like this

Adjacent prediction questions.

How we compute these odds

SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.

For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.

Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.

Last updated on this page: just now.